[go: up one dir, main page]

AR003475A1 - Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion. - Google Patents

Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion.

Info

Publication number
AR003475A1
AR003475A1 ARP960103900A AR10390096A AR003475A1 AR 003475 A1 AR003475 A1 AR 003475A1 AR P960103900 A ARP960103900 A AR P960103900A AR 10390096 A AR10390096 A AR 10390096A AR 003475 A1 AR003475 A1 AR 003475A1
Authority
AR
Argentina
Prior art keywords
peptides
preparation
new
phe
formulations
Prior art date
Application number
ARP960103900A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR003475A1 publication Critical patent/AR003475A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP960103900A 1995-08-18 1996-08-06 Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion. AR003475A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides

Publications (1)

Publication Number Publication Date
AR003475A1 true AR003475A1 (es) 1998-08-05

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103900A AR003475A1 (es) 1995-08-18 1996-08-06 Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion.

Country Status (27)

Country Link
US (1) US6337319B1 (da)
EP (1) EP0845003B1 (da)
JP (1) JPH11512086A (da)
KR (1) KR19990037677A (da)
CN (1) CN1200127A (da)
AR (1) AR003475A1 (da)
AT (1) ATE210148T1 (da)
AU (1) AU711862B2 (da)
BR (1) BR9610248A (da)
CA (1) CA2229797A1 (da)
CZ (1) CZ287299B6 (da)
DE (1) DE69617699T2 (da)
DK (1) DK0845003T3 (da)
EE (1) EE9800048A (da)
ES (1) ES2171224T3 (da)
HU (1) HUP9901209A3 (da)
IL (1) IL123258A (da)
IS (1) IS4664A (da)
NO (1) NO980592L (da)
NZ (1) NZ315809A (da)
PL (1) PL325113A1 (da)
RU (1) RU2165432C2 (da)
SE (1) SE9503924D0 (da)
SK (1) SK282469B6 (da)
TR (1) TR199800258T1 (da)
TW (1) TW424095B (da)
WO (1) WO1997007130A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
AU6730500A (en) * 1999-08-25 2001-03-19 Daiichi Fine Chemical Co., Ltd. Medicinal composition for percutaneous/permucosal absorption
AU1623801A (en) 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
AU2001277908A1 (en) 2000-07-18 2002-01-30 Cornell Research Foundation Inc. Medicinal uses of mu-opioid receptor agonists
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7825231B2 (en) 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
CA2667155C (en) 2006-11-10 2016-05-10 Cara Therapeutics, Inc. Synthetic peptide amides
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2273983B1 (en) * 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2997965B1 (en) 2009-07-22 2019-01-02 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
NZ315809A (en) 1999-05-28
AU6760096A (en) 1997-03-12
TR199800258T1 (xx) 1998-05-21
EP0845003A1 (en) 1998-06-03
BR9610248A (pt) 1999-07-06
US6337319B1 (en) 2002-01-08
HUP9901209A2 (hu) 1999-08-30
CZ40198A3 (cs) 1998-08-12
DK0845003T3 (da) 2002-07-15
ATE210148T1 (de) 2001-12-15
TW424095B (en) 2001-03-01
DE69617699D1 (de) 2002-01-17
CA2229797A1 (en) 1997-02-27
RU2165432C2 (ru) 2001-04-20
SE9503924D0 (sv) 1995-11-07
SK282469B6 (sk) 2002-02-05
JPH11512086A (ja) 1999-10-19
IS4664A (is) 1998-02-04
WO1997007130A1 (en) 1997-02-27
AU711862B2 (en) 1999-10-21
EE9800048A (et) 1998-08-17
NO980592D0 (no) 1998-02-11
CN1200127A (zh) 1998-11-25
IL123258A0 (en) 1998-09-24
PL325113A1 (en) 1998-07-06
IL123258A (en) 2003-03-12
DE69617699T2 (de) 2003-08-07
CZ287299B6 (en) 2000-10-11
KR19990037677A (ko) 1999-05-25
ES2171224T3 (es) 2002-09-01
NO980592L (no) 1998-02-11
HUP9901209A3 (en) 2000-12-28
EP0845003B1 (en) 2001-12-05
SK20398A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
AR003475A1 (es) Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion.
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
PH16791A (en) Angiotensin-ii analogues with antagonizing effects,containing an ester group in position 8
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
SE9604341D0 (sv) Hepta-peptide oxytocin analogue
AR003966A1 (es) Un derivado de difenilmetilenpiperidina, composición farmacéutica que lo contiene, metodo de preparación de dicho derivado y uso de este ultimo para preparar un medicamento
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
MX9400255A (es) Analogos de peptidos opioides, metodo para su preparacion y composiciones farmaceuticas que los incluyen.
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
EP0553113A4 (da)
ES2174220T3 (es) Uso de derivados de 4-fenil-3,6-dihidro-2h-piridilo como agentes bloqueantes de subtipos de receptores nmda.
ES2171445T3 (es) Nuevos oligopeptidos con afinidad para receptores opioides.
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase

Legal Events

Date Code Title Description
FG Grant, registration